Properdin: New roles in pattern recognition and target clearance

Molecular Immunology

Volumn 45, Issue 16, 2008, Pages 4048-4056

  Kemper, Claudia ^a   Hourcade, Dennis E ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Complement; Complement alternative pathway; Glycosaminoglycans; Neutrophils; Pattern recognition; Phagocytosis; Properdin

Indexed keywords

COMPLEMENT; PROPERDIN;

ANIMAL; BIOLOGICAL MODEL; COMPLEMENT ALTERNATIVE PATHWAY; HUMAN; IMMUNOLOGY; METABOLISM; REVIEW;

ANIMALS; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT SYSTEM PROTEINS; HUMANS; MODELS, IMMUNOLOGICAL; PROPERDIN;

EID: 55949096010     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.06.034     Document Type: Review

References (91)

1. Braconier, J.H., Sjoholm, A.G., Soderstrom, C., 1983. Fulminant meningococcal infections in a family with inherited deficiency of properdin. Scand. J. Infect. Dis. 15, 339-345.
2. Couvreur, B., Beaufays, J., Charon, C., Lahaye, K., Gensale, F., Denis, V., Charloteaux, B., Decrem, Y., Prevot, P.P., Brossard, M., Vanhamme, L., Godfroid, E., 2008. Variability and action mechanism of a family of anticomplement proteins in Ixodes ricinus. PLoS ONE 3, e1400.
3. Daser, A., Meissner, N., Herz, U., Renz, H., 1995. Role and modulation of T-cell cytokines in allergy. Curr. Opin. Immunol. 7, 762-770.
4. DeLano, W.L., 2002. The PyMOL Molecular Graphics System, DeLano Scientific, Palo Alto, CA, USA. http://www.pymol.org.
5. Dempsey, P.W., Allison, M.E., Akkaraju, S., Goodnow, C.C., Fearon, D.T., 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271, 348-350.
6. Densen, P., 1989. Interaction of complement withNeisseria meningitidis andNeisseria gonorrhoeae. Clin. Microbiol. Rev. 2 Suppl., S11-S17.
7. Densen, P., Weiler, J.M., Griffiss, J.M., Hoffmann, L.G., 1987. Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination. New Engl. J. Med. 316, 922-926.
8. DiScipio, R.G., 1981. The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan. Biochem. J. 199, 485-486.
9. Ecker, E.E., 1958. Louis Pillemer, 1908-1957. J. Immunol. 80, 415-416.
10. Elliott, M.K., Jarmi, T., Ruiz, P., Xu, Y., Holers, V.M., Gilkeson, G.S., 2004. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int. 65, 129-138.
11. Elward, K., Griffiths, M., Mizuno, M., Harris, C.L., Neal, J.W., Morgan, B.P., Gasque, P., 2005. CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J. Biol. Chem. 280, 36342-36354.
12. Esko, J.D., Selleck, S.B., 2002. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 71, 435-471.
13. Fadok, V.A., Bratton, D.L., Rose, D.M., Pearson, A., Ezekewitz, R.A., Henson, P.M., 2000. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405, 85-90.
14. Farries, T.C., Lachmann, P.J., Harrison, R.A., 1988. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products. Biochem. J. 252, 47-54.
15. Fearon, D.T., 1979. Activation of the alternative complement pathway. CRC Crit. Rev. Immunol. 1, 1-32.
16. Fearon, D.T., Austen, K.F., 1975. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J. Exp. Med. 142, 856-863.
17. Figueroa, J.E., Densen, P., 1991. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4, 359-395.
18. Fung, M., Loubser, P.G., Undar, A., Mueller, M., Sun, C., Sun, W.N., Vaughn, W.K., Fraser Jr., C.D., 2001. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J. Thorac. Cardiovasc. Surg. 122, 113-122.
19. Fuster, M.M., Esko, J.D., 2005. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5, 526-542.
20. Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J.M., Kraus, D., Hollmann, T.J., Casali, P., Caroll, M.C., Wetsel, R.A., Lambris, J.D., Holers, V.M., Salmon, J.E., 2003. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 112, 1644-1654.
21. Griffiss, J.M., Schneider, H., Mandrell, R.E., Yamasaki, R., Jarvis, G.A., Kim, J.J., Gibson, B.W., Hamadeh, R., Apicella, M.A., 1988. Lipooligosaccharides: the principal glycolipids of the neisserial outer membrane. Rev. Infect. Dis. 10 (Suppl. 2), S287-S295.
22. Gupta-Bansal, R., Parent, J.B., Brunden, K.R., 2000. Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. Mol. Immunol. 37, 191-201.
23. Hartmann, S., Hofsteenge, J., 2000. Properdin, the positive regulator of complement, is highly C-mannosylated. J. Biol. Chem. 275, 28569-28574.
24. Hawlisch, H., Kohl, J., 2006. Complement and Toll-like receptors: key regulators of adaptive immune responses. Mol. Immunol. 43, 13-21.
25. Heeger, P.S., Lalli, P.N., Lin, F., Valujskikh, A., Liu, J., Muqim, N., Xu, Y., Medof, M.E., 2005. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 201, 1523-1530.
26. Heinrichs, D.E., Yethon, J.A., Amor, P.A., Whitfield, C., 1998. The assembly system for the outer core portion of R1- and R4-type lipopolysaccharides of Escherichia coli. The R1 core-specific beta-glucosyltransferase provides a novel attachment site for O-polysaccharides. J. Biol. Chem. 273, 29497-29505.
27. Helmy, K.Y., Katschke Jr., K.J., Gorgani, N.N., Kljavin, N.M., Elliott, J.M., Diehl, L., Scales, S.J., Ghilardi, N., van Lookeren Campagne, M., 2006. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124, 915-927.
28. Hochberg, M.C., 1992. Epidemiology of systemic lupus erythematosus. In: Lahita, R.G. (Ed.), Systemic Lupus Erythematosus. Churchill Livingstone, Inc., New York, pp. 103-117.
29. Holme, E.R., Veitch, J., Johnston, A., Hauptmann, G., Uring-Lambert, B., Seywright, M., Docherty, V., Morley, W.N., Whaley, K., 1989. Familial properdin deficiency associated with chronic discoid lupus erythematosus. Clin. Exp. Immunol. 76, 76-81.
30. Hourcade, D., 2006. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J. Biol. Chem. 281, 2128-2132.
31. Janssen, B.J., Gros, P., 2007. Structural insights into the central complement component C3. Mol. Immunol. 44, 3-10.
32. Ji, H., Ohmura, K., Mahmood, U., Lee, D.M., Hofhuis, F.M., Boackle, S.A., Takahashi, K., Holers, V.M., Walport, M., Gerard, C., Ezekowitz, A., Carroll, M.C., Brenner, M., Weissleder, R., Verbeek, J.S., Duchatelle, V., Degott, C., Benoist, C., Mathis, D., 2002. Arthritis critically dependentoninnate immunesystemplayers. Immunity 16, 157-168.
33. Jones, J., Morgan, B.P., 1995. Apoptosis is associated with reduced expression of complement regulatory molecules, adhesion molecules and other receptors on polymorphonuclear leucocytes: functional relevance and role in inflammation. Immunology 86, 651-660.
34. Kemper, C., Atkinson, J.P., 2007. T-cell regulation: with complements from innate immunity. Nat. Rev. Immunol. 7, 9-18.
35. Kemper, C., Mitchell, L.M., Zhang, L., Hourcade, D.E., 2008. The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis. Proc. Natl. Acad. Sci. U.S.A. 105, 9023-9028.
36. Kerr, J.F., Wyllie, A.H., Currie, A.R., 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239-257.
37. Kimura, Y., Miwa, T., Zhou, L., Song, W.C., 2008. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood 111, 732-740.
38. Kohler, P.F., Muller-Eberhard, H.J., 1967. Immunochemical quantitation of the third, fourth and fifth components of human complement: concentrations in the serum of healthy adults. J. Immunol. 99, 1211-1216.
39. Kolble, K., Reid, K.B., 1993. Genetic deficiencies of the complement system and association with disease-early components. Int. Rev. Immunol. 10, 17-36.
40. Korb, L.C., Ahearn, J.M., 1997. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes. J. Immunol. 158, 4525-4528.
41. Law, S.K., Levine, R.P., 1977. Interactions between the third complement protein and cell surface macromolecules. Proc. Natl. Acad. Sci. U.S.A. 74, 2701-2705.
42. Lepow, I.H., 1980. Presidential address to American Association of Immunologists in Anaheim, California, April 16, 1980. Louis Pillemer, Properdin, and scientific controversy. J. Immunol. 125, 471-475.
43. Liu, J., Miwa, T., Hilliard, B., Chen, Y., Lambris, J.D., Wells, A.D., Song, W.C., 2005. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J. Exp. Med. 201, 567-577.
44. Medzhitov, R., Janeway, C.J., 2002. Decoding the patterns of self and non-self by the innate immune system. Science 296, 298-300.
45. Medicus, R.G., Gotze, O., Muller-Eberhard, H.J., 1976. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J. Exp. Med. 144, 1076-1093.
46. Mevorach, D., Mascarenhas, J.O., Gershov, D., Elkon, K.B., 1998. Complementdependent clearance of apoptotic cells by human macrophages. J. Exp. Med. 188, 2313-2320.
47. Nauta, A.J., Raaschou-Jensen, N., Roos, A., Daha, M.R., Madsen, H.O., Borrias-Essers, M.C., Ryder, L.P., Koch, C., Garred, P., 2003. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur. J. Immunol. 33, 2853-2863.
48. Nelson Jr., R.A., 1958. An alternative mechanism for the properdin system. J. Exp. Med. 108, 515-535.
49. Nolan, K.F., Reid, K.B., 1993. Properdin. Methods Enzymol. 223, 35-46.
50. Nolan, K.F., Schwaeble, W., Kaluz, S., Dierich, M.P., Reid, K.B., 1991.Molecular cloning of the cDNA coding for properdin, a positive regulator of the alternative pathway of human complement. Eur. J. Immunol. 21, 771-776.
51. Oglesby, T.J., Ueda, A., Volanakis, J.E., 1988. Radioassays for quantitation of intact complement proteins C2 and B in human serum. J. Immunol. Methods 110, 55-62.
52. Panetti, T.S., Kudryk, B.J., Mosher, D.F., 1999. Interaction of recombinant procollagen and properdin modules of thrombospondin-1 with heparin and fibrinogen/fibrin. J. Biol. Chem. 274, 430-437.
53. Pangburn, M.K., Muller-Eberhard, H.J., 1984. The alternative pathway of complement. Springer Semin. Immunopathol. 7, 163-192.
54. Pangburn, M.K., Muller-Eberhard, H.J., 1986. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem. J. 235, 723-730.
55. Pillemer, L., 1954. The properdin systemand immunity. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120, 279-285.
56. Ratnoff, W.D., 1980. A war with the molecules: Louis Pillemer and the history of properdin. Perspect. Biol. Med. 23, 638-657.
57. Ren, Y., Silverstein, R.L., Allen, J., Savill, J., 1995. CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis. J. Exp. Med. 181, 1857-1862.
58. Roos, A., Xu, W., Castellano, G., Nauta, A.J., Garred, P., Daha, M.R., van Kooten, C., 2004. Mini-review: a pivotal role for innate immunity in the clearance of apoptotic cells. Eur. J. Immunol. 34, 921-929.
59. Sacks, S.H., Zhou, W., 2003. Locally produced complement and its role in renal allograft rejection. Am. J. Transplant. 3, 927-932.
60. Savill, J., Dransfield, I., Gregory, C., Haslett, C., 2002. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2, 965-975.
61. Schwaeble, W., Dippold, W.G., Schafer, M.K., Pohla, H., Jonas, D., Luttig, B., Weihe, E., Huemer, H.P., Dierich, M.P., Reid, K.B., 1993. Properdin, a positive regulator of complement activation, is expressed in human T cell lines and peripheral blood T cells. J. Immunol. 151, 2521-2528.
62. Schwaeble, W., Huemer, H.P., Most, J., Dierich, M.P., Strobel, M., Claus, C., Reid, K.B., Ziegler-Heitbrock, H.W., 1994. Expression of properdin in human monocytes. Eur. J. Biochem. 219, 759-764.
63. Schwaeble, W.J., Reid, K.B., 1999. Does properdin crosslink the cellular and the humoral immune response? Immunol. Today 20, 17-21.
64. Sjoblom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D., Mandelker, D., Leary, R.J., Ptak, J., Silliman, N., Szabo, S., Buckhaults, P., Farrell, C., Meeh, P., Markowitz, S.D., Willis, J., Dawson, D., Willson, J.K., Gazdar, A.F., Hartigan, J., Wu, L., Liu, C., Parmigiani, G., Park, B.H., Bachman, K.E., Papadopoulos, N., Vogelstein, B., Kinzler, K.W., Velculescu, V.E., 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274.
65. Sjoeholm, A.G., Kuijper, E.J., Tijssen, C.C., Jansz, A., Bol, P., Spanjaard, L., Zanen, H.C., 1988. Dysfunctional properdin in a Dutch family with meningococcal disease. New Engl. J. Med. 319, 33-37.
66. Smith, C.A., Pangburn, M.K., Vogel, C.W., Muller-Eberhard, H.J., 1984. Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. J. Biol. Chem. 259, 4582-4588.
67. Spitzer, D., Mitchell, L.M., Atkinson, J.P., Hourcade, D.E., 2007. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for De Novo convertase assembly. J. Immunol. 179, 2600-2608.
68. Stevens, B., Allen, N.J., Vazquez, L.E., Howell, G.R., Christopherson, K.S., Nouri, N., Micheva, K.D., Mehalow, A.K., Huberman, A.D., Stafford, B., Sher, A., Litke, A.M., Lambris, J.D., Smith, S.J., John, S.W.M., Barres, B.A., 2007. The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164-1178.
69. Stover, C.M., Luckett, J.C., Echtenacher, B., Dupont, A., Figgitt, S.E., Brown, J., Mannel, D.N., Schwaeble, W.J., 2008. Properdin plays a protective role in polymicrobial septic peritonitis. J. Immunol. 180, 3313-3318.
70. Strainic, M.G., Liu, J., Huang, D., An, F., Lalli, P.N., Muqim, N., Shapiro, V.S., Dubyak, G.R., Heeger, P.S., Medof, M.E., 2008. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28, 425-435.
71. Tan, K., Duquette, M., Liu, J.H., Dong, Y., Zhang, R., Joachimiak, A., Lawler, J., Wang, J.H., 2002. Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J. Cell Biol. 159, 373-382.
72. Thurman, J.M., Kraus, D.M., Girardi, G., Hourcade, D., Kang, H.J., Royer, P.A., Mitchell, L.M., Giclas, P.C., Salmon, J., Gilkeson, G., Holers, V.M., 2005. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibodyinduced pregnancy loss in mice. Mol. Immunol. 42, 87-97.
73. Tossavainen, H., Pihlajamaa, T., Huttunen, T.K., Raulo, E., Rauvala, H., Permi, P., Kilpelainen, I., 2006. The layered fold of the TSR domain of P. falciparum TRAP contains a heparin binding site. Protein Sci. 15, 1760-1768.
74. Trouw, L.A., Blom, A.M., Gasque, P., 2008. Role of complement and complement regulators in the removal of apoptotic cells. Mol. Immunol. 45, 1199-1207.
75. Tsao, N., Tsai, W.H., Lin, Y.S., Chuang, W.J., Wang, C.H., Kuo, C.F., 2006. Streptococcal pyrogenic exotoxin B cleaves properdin and inhibits complement-mediated opsonophagocytosis. Biochem. Biophys. Res. Commun. 339, 779-784.
76. Tyson, K.R., Elkins, C., de Silva, A.M., 2008. A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin. J. Immunol. 180, 3964-3968.
77. Verhoven, B., Schlegel, R.A., Williamson, P., 1995. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J. Exp. Med. 182, 1597-1601.
78. Volanakis, J.E., 1998. Overview of the complement system. In: Volanakis, J.E., Frank, M.M. (Eds.), The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York, pp. 9-32.
79. Wagner, J.G., Roth, R.A., 2000. Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature. Pharmacol. Rev. 52, 349-374.
80. Walport, M.J., 2001a. Complement. Second of two parts. New Engl. J. Med. 344, 1140-1144.
81. Walport, M.J., 2001b. Complement. First of two parts. New Engl. J. Med. 344, 1058-1066.
82. Watanabe, H., Garnier, G., Circolo, A., Wetsel, R.A., Ruiz, P., Holers, V.M., Boackle, S.A., Colten, H.R., Gilkeson, G.S., 2000. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J. Immunol. 164, 786-794.
83. Wechsler, A.S., Gordon, M.C., Dendorfer, U., LeClair, K.P., 1994. Induction of IL-8 expression in T cells uses the CD28 costimulatory pathway. J. Immunol. 153, 2515-2523.
84. Whaley, K., 1985. An introduction to the complement system. In: Whaley, K. (Ed.), Methods inComplement for Clinical Immunologists. Churchill Livingstone, Edinburgh, pp. 1-20.
85. Wipke, B.T., Allen, P.M., 2001. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J. Immunol. 167, 1601-1608.
86. Wirthmueller, U., Dewald, B., Thelen, M., Schafer, M.K., Stover, C., Whaley, K., North, J., Eggleton, P., Reid, K.B., Schwaeble, W.J., 1997. Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. J. Immunol. 158, 4444-4451.
87. Wright, S.D., Silverstein, S.C., 1983. Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes. J. Exp. Med. 158, 2016-2023.
88. Xiao, H., Schreiber, A., Heeringa, P., Falk, R.J., Jennette, J.C., 2007. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am. J. Pathol. 170, 52-64.
89. Xu, W., Berger, S.P., Trouw, L.A., de Boer, H.C., Schlagwein, N., Mutsaers, C., Daha, M., van Kooten, C., 2008. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathwaycomplement activation. J. Immunol. 180, 7613-7621.
90. Yu, H., Munoz, E.M., Edens, R.E., Linhardt, R.J., 2005. Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance. Biochim. Biophys. Acta 1726, 168-176.
91. Zhang, L., Lawrence, R., Frazier, B.A., Esko, J.D., 2006. CHO glycosylation mutants: proteoglycans. Methods Enzymol. 416, 205-221.